Key Points<\/p>\n
Two issues holding down Pfizer might not be as significant as they seem.<\/p>\n<\/li>\n
Prudential’s long-term growth prospects remain solid.<\/p>\n<\/li>\n
Verizon’s underlying business is strong, with growth likely to accelerate in the coming years.<\/p>\n<\/li>\n
The stock market is richly valued. Warren Buffett knows it. Federal Reserve chair Jerome Powell knows it. You and I know it, too.<\/p>\n
Does that mean there aren’t any good stocks to buy right now? Nope. Some are even bargains. Here are three dirt cheap stocks to buy in a market priced for perfection.<\/p>\n
Where to invest $1,000 right now?<\/strong> Our analyst team just revealed what they believe are the 10 best stocks <\/strong>to buy right now, when you join Stock Advisor. See the stocks \u00bb<\/strong><\/a><\/p>\n 1. Pfizer<\/p>\n Pfizer<\/strong> (NYSE: PFE)<\/a> stock trades at a forward price-to-earnings ratio<\/a> of under 8x. To put this valuation into context, the S&P 500<\/strong> (SNPINDEX: ^GSPC) healthcare sector trades at 17 times forward earnings. <\/p>\n When a stock is this cheap, it’s important to find out why. In Pfizer’s case, several factors are at work. Many investors are worried about the company’s looming patent cliff<\/a>. The uncertain impact of the Trump administration’s trade policies on the biopharmaceutical industry has also been a big concern.<\/p>\n However, we can take one of those issues off the table (at least, for the most part). Pfizer recently announced a deal with the White House<\/a> that exempts it from any pharmaceutical tariffs<\/a> over the next three years. The company will slash the prices for many of its products and invest more in U.S. manufacturing. But the positives of eliminating the uncertainty seem to outweigh the negatives.<\/p>\n That patent cliff might not be as significant a problem as some think, either. Pfizer has multiple rising stars in its lineup that should largely offset any losses related to patent expirations. Its pipeline also features several highly promising programs.<\/p>\n In the meantime, Pfizer looks like an income investor’s dream stock. Its forward dividend yield<\/a> tops 6.3%. Management remains committed to maintaining and growing the dividend, too.<\/p>\n 2. Prudential Financial<\/p>\n Prudential Financial<\/strong> (NYSE: PRU)<\/a> is even cheaper than Pfizer. Its forward earnings multiple currently hovers around 7.5. That’s less than half the multiple of the S&P 500 financial sector.<\/p>\n Sure, Prudential’s revenue and earnings have fallen recently compared to the prior year period. Most of this decline stemmed from volatility associated with the company’s variable annuities unit. However, Prudential has now exited this business. <\/p>\n I think Prudential’s long-term prospects remain solid. Wall Street seems to have the same view. The stock’s price-to-earnings-to-growth (PEG) ratio<\/a> is only 0.58. Since this metric is based on analysts’ five-year earnings growth projections, the super-low PEG ratio indicates optimism about Prudential’s growth.<\/p>\n The good news is that Prudential doesn’t have to deliver exceptional share price appreciation going forward to generate double-digit total returns. Its forward dividend yield is 5.2%. <\/p>\n 3. Verizon Communications<\/p>\n Last, but not least, is Verizon Communications<\/strong> (NYSE: VZ)<\/a>. This telecommunications giant’s shares trade at around nine times forward earnings. That’s a significantly lower valuation than its biggest rivals, AT&T<\/strong> (NYSE: T)<\/a> and T-Mobile US<\/strong> (NASDAQ: TMUS)<\/a> have.<\/p>\n Unlike Pfizer and Prudential, Verizon has delivered a decent gain for investors so far this year. This reflects the company’s underlying business strength. In the second quarter of 2025, Verizon posted the strongest year-over-year revenue growth in the wireless services industry. It also captured additional market share in broadband. As a result of this Q2 performance, the company raised its full-year guidance for adjusted earnings per share, adjusted EBITDA<\/a>, and free cash flow<\/a>. <\/p>\n Verizon’s total return this year is much higher than its share gains. That’s to be expected since the company’s dividend yields a lofty 6.3%. The telecom leader has also increased its dividend for 19 consecutive years. <\/p>\n To be sure, telecommunications isn’t a high-growth market. However, I expect that Verizon’s growth will accelerate over the next few years for two key reasons. First, the company should close its pending acquisition of Frontier Communications<\/strong> (NASDAQ: FYBR)<\/a> in early 2026. Second, 6G networks should begin to roll out by 2030, creating a major opportunity for Verizon.<\/p>\n Should you invest $1,000 in Pfizer right now?<\/p>\n Before you buy stock in Pfizer, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a><\/strong> for investors to buy now\u2026 and Pfizer wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix<\/strong> made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $621,976<\/strong>!* Or when Nvidia<\/strong> made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,150,085<\/strong>!*<\/p>\n Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,058% \u2014 a market-crushing outperformance compared to 191% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor.<\/p>\n See the 10 stocks \u00bb<\/strong><\/a><\/p>\n *Stock Advisor returns as of September 29, 2025<\/p>\n Keith Speights<\/a> has positions in Pfizer, Prudential Financial, and Verizon Communications. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends T-Mobile US and Verizon Communications. The Motley Fool has a disclosure policy<\/a>.<\/p>\n The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Two issues holding down Pfizer might not be as significant as they seem. Prudential’s long-term growth…\n","protected":false},"author":2,"featured_media":13297,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[175],"tags":[79,18,19,17,188],"class_list":{"0":"post-104262","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-eire","10":"tag-ie","11":"tag-ireland","12":"tag-markets"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/104262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=104262"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/104262\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/13297"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=104262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=104262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=104262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}